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Abstract
Background: This study was conducted to evaluate the expression of the activated leukocyte cell adhesion molecule
(ALCAM) in pancreatic cancer (PAC) and to determine whether or not the ectodomain shedding of ALCAM (s-ALCAM) could
serve as a biomarker in the peripheral blood of PAC patients.
Material and Methods: Tissue specimens and blood sera of patients with PAC (n=264 and n=116, respectively) and the
sera of 115 patients with chronic pancreatitis (CP) were analyzed via ALCAM immunohistochemistry and s-ALCAM ELISA
tests. Results were correlated with clinical, histopathological, and patient survival data (Chi-square test, Kaplan-Meier
analysis, log-rank test, respectively).
Results: ALCAM was expressed in the majority of PAC lesions. Immunohistochemistry and serum ELISA tests revealed no
association between ALCAM expression in primary tumors or s-ALCAM and clinical or histopathological data. Neither
ALCAM nor s-ALCAM showed a significant impact regarding overall survival (p=0.261 and p=0.660, respectively). S-ALCAM
serum levels were significantly elevated compared to the sera of CP patients (p,0.001). The sensitivity of s-ALCAM in
detecting PAC was 58.6% at a specificity of 73.9% (AUC=0.69).
Conclusions: ALCAM is expressed in the majority of PAC lesions, but statistical analysis revealed no association with clinical
or pathological data. Although significantly elevated in patients with PAC, the sensitivity and specificity of the s-ALCAM
serum quantification test was low. Therefore, its potential as a novel diagnostic marker for PAC remains elusive and further
investigations are required.
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Introduction
Since most patients with pancreatic adenocarcinoma (PAC)
present in advanced stages of the disease, the incidence of PAC is
nearly equal to its mortality. Even in the curative setting, which
only applies to a subset of patients, oncological long-term survival
has not significantly improved over recent years (reported median
survival of between 14 and 22 months); most of the tumors recur
locally or at distant sites [1,2]. Unfortunately, improvements in
(neo-) adjuvant and even palliative treatment regarding recurrence
and survival are still disappointing; none of the recently tested
targeted therapies were very promising in clinical trials [3,4,5,6].
As a consequence, two main goals must be achieved: first, new
biochemical tests for the early detection, monitoring and prognosis
of PAC should be developed. In addition, these could help to
distinguish between malignant and benign pancreatic lesions, such
as chronic pancreatitis (CP). In fact, there are still no established or
recommended serum markers for the diagnosis or prognosis of
PAC in routine use [7,8]. Secondly, potential innovative targets for
biological therapies must be identified to improve the survival of
patients with PAC.
In recent times, the theory of the hierarchical organization of
tumor cells was extensively investigated, supporting the cancer
stem cell hypothesis [9,10,11,12,13]. These cells might be potential
therapeutic biologic targets and prognostic markers. Several
authors have identified putative stem cell markers for intestinal
as well as PAC, namely CD133, CD44, and CD166, the activated
leukocyte cell adhesion molecule (ALCAM) [10,14,15,16,17]. The
latter is a highly conserved 110 kDa multidomain transmembrane
type 1 glycoprotein of the immunoglobulin superfamily. This
molecule mediates homotypic and heterotypic interactions be-
tween cells [18,19]. It plays a role in the development of different
tissues, for example in neurogenesis and haemotopoiesis, and it
participates in the mechanisms of the immune response
[20,21,22]. As with other membrane proteins, ALCAM represents
a potential target for therapy and its utility as a drug target
structure may be further enhanced by ligand-induced endocytosis
[23]. Moreover, a recently described internalizing single-chain
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agents into cancer cells [23,24].
Several studies reported its potential as a biomarker for different
tumor entities, such as melanoma, pancreatic and ampullary
adenocarcinoma, and colorectal, gynecological and neuroendo-
crine carcinomas. Its expression is associated with diverse
outcomes in different tumors [17,18,19,20,25,26,27,28,29,30,
31,32]. Furthermore, the extracellular domain of ALCAM (s-
ALCAM) is shed by metalloproteases (for example, ADAM 17),
functions as an active messenger and interacts with surrounding
tissues [33]. After cleavage from the tumor cell surface, s-ALCAM
can be detected in the blood serum. An increased levels of s-
ALCAM expression was observed in ovarian, breast and
esophageal cancer patients compared to healthy controls [30,33,
34,35,36]. In addition, studies with small patient samples showed
an elevation of s-ALCAM expression in the sera of patients with
PAC [37,38].
We conducted the present study to investigate the association
between ALCAM expression in a large number of primary PAC
lesions and clinical and histopathological data and its potential
prognostic value. Furthermore, we determined the preoperative s-
ALCAM serum levels of patients with PAC and CP and evaluated
its significance as a diagnostic and prognostic marker.
Results
Characteristics of the Patients
Pancreatic cancer tissue specimens from 264 patients aged 33 to
87 years (median 63 years) and blood sera from 116 PAC patients
aged between 33 and 92 years (median 64 years) and 115 CP
patients aged between 31 und 79 (median 51 years) were included
in this study. All patients were surgically treated between 1993 and
2006 in the Department of General, Visceral and Thoracic
Surgery of the University Medical Center Hamburg-Eppendorf,
Germany.
The operation methods used were the classic Whipple
procedure, pylorus-preserving pancreaticoduodenectomy, subtotal
or total pancreatectomy in cases of PAC and organ-preserving
resection methods in cases of CP.
The median follow-up time of the patients included in the
survival analysis was 14 months (range 0–193 months) and the
median overall survival (OS) was 15 months (95% CI 13.2–16.7
months). Twenty-nine (10.5%) patients died within the first 30
days after surgery.
ALCAM Expression in PAC and its Correlation with
Clinical and Histopathological Characteristics
A total of 192 (78.6%) primary PAC tumor samples were
interpretable in our tissue microarryay (TMA) analysis. Reasons
for non-informative cases (52; 21.3%) included a complete lack of
tissue samples or the absence of unequivocal cancer tissue in the
TMA sections. Analysis of healthy pancreatic tissue revealed a
weak or intermediate ALCAM expression (+/++) in normal acinar
or ductal pancreatic cells (n=10, Figure 1F). The staining pattern
of the ALCAM immunohistochemistry shows a predominant
membranous expression of the ALCAM molecule. Although some
cytoplasmatic staining was occasionally seen, this was always
associated with a much greater level of staining in the membranes.
Thirty-eight per cent of the tumors showed a low level of ALCAM
expression, 44% medium and 18% a high level of ALCAM
expression (Figure 1A–1E, see Material and Methods for criteria).
The tumors show a heterogeneous staining pattern inside the
cancerous lesions (Figure 1A–1E).
The histopathological findings of the interpretable tumors are
summarized in Table 1. The expression of ALCAM showed no
association with clinical or histopathological parameters such as
age, sex, tumor stage (UICC 6
th classification) or tumor grade (G).
The overall survival curves plotted by the Kaplan-Meier
analysis did not reveal a significant difference between low,
medium or high ALCAM-expression patients (p=0.261,
Figure 2A). Due to this, no multivariate analysis was performed.
S-ALCAM in Blood Serum
The s-ALCAM values were significantly elevated in the blood
serum of PAC patients (n=116, mean 29.4 ng/ml, standard
deviation (SD) 1.1 ng/ml, p,0.001) compared to CP patients
(n=115, mean 18.2 ng/ml, SD 1.0 ng/ml) and healthy blood
donors (n=128, mean 21.1 ng/ml, SD 0.7 ng/ml, Figure 3A).
Receiver operating characteristic curves were used to establish
the sensitivity-specificity relationship for s-ALCAM (Figure 3B).
The cut-off level determined by the Youden index was 22 ng/ml.
The AUC was 0.690. The sensitivity of s-ALCAM in detecting
PAC was 58.6% at a specificity of 73.9% compared to patients
with CP.
In order to determine the impact of elevated s-ALCAM levels
on patients with PAC, continuous and categorical analyses were
perfomed.
No significant differences were found regarding sex (female
33.6 ng/ml, male 31.3 ng/ml, p=0.649), age (,64 years
33.0 ng/ml, .64 years 33.0 ng/ml; p=0.775), UICC stage (Ia
24.1 ng/ml, Ib 36.0 ng/ml, IIa 26.8 ng/ml, IIb 36.4 ng/ml, III
19.0 ng/ml; IV 28.1 ng/ml; p=0.277) and tumor cell grading
(G1 and G2 31.1 ng/ml, G3 35.0 ng/ml; p=0.479).
We defined different cut-off values for the categorical analysis of
the s-ALCAM data. With none of them, (25
th percentile, median
and 75
th percentile, the ‘optimal cut-off value’, determined using
the Youden-index for discrimination of the UICC classification
and tumor cell grading) a significant association with clinical or
histopathological parameters was calculated.
To illustrate this, Table 1 presents the analysis with a cut-off
value of the 75
th percentile (,42.3 ng/ml s-ALCAM, ,75
th
percentile; Table 1). The overall survival curves plotted by the
Kaplan-Meier analysis showed no significant differences between
the low and high s-ALCAM groups (p=0.660, Figure 2B). Due to
this, no multivariate analysis was performed. Furthermore, no
association was found regarding age or sex in both PAC and CP.
In addition, there was no significant correlation between the s-
ALCAM groups and the ALCAM immunohistochemical staining
results (n=39; p=0.699).
Discussion
The aim of the current study was to evaluate the expression and
clinical significance of ALCAM in PAC tissues and to determine
whether or not s-ALCAM could serve as a diagnostic and
prognostic marker in the peripheral blood of PAC patients. The
results showed that ALCAM was expressed in the majority of PAC
lesions and that s-ALCAM serum levels were significantly elevated
compared to the sera of CP patients and healthy controls
(p,0.001).
The correlation between ALCAM expression in the primary
PAC lesions with the clinical and pathological parameters revealed
no significant findings, which confirms the results of recently
published studies on smaller patient samples [29,37]. Nonetheless,
the same authors described a potential role of ALCAM in cell
adhesion reduction and the induction of chemoresistance in vitro
[37], and ALCAM was also described as an independent
ALCAM (CD166) in Pancreatic Cancer
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findings by Kahlert and colleagues, an overall survival analysis of
our results (n=138) showed no significant association between
time of survival and the intensity and quantity of ALCAM
expression (low, medium or high) (p=0.261, Figure 2A).
The localizationofALCAMexpressioninpancreaticcancercells
was previously described as being mainly cytoplasmatic in PAC
specimens [29]. In contrast to these results, the immunohistochem-
ical staining protocol in the present study revealed a predominantly
membranous expression of the adhesion molecule ALCAM
(Figure 1) [27,30,31,32]. Cytoplasmatic staining intensity was
related to the intensity of the membranous staining and did not
occur in the absence of membranous staining. Similar observations
were made by Kristiansen and colleagues, who also found
predominantly membranous staining with a variable degree of
cytoplasmic staining [39]. In addition, we did not observe a
membranous-cytoplasmaticshiftbetweennormalductalcellsorlow
grade and high grade tumors as Kahlert and colleagues did [29].
Why are there discrepancies in the morphologic and statistical
results of studies investigating ALCAM in PAC? Of course,
multiple factors influence the staining intensity and specificity of
immunohistochemistry, and antibody concentration is only one of
them. Used dilutions range from 1:100 to 1:450 and different pre-
treatments are described in the studies, reflecting the general
problem of comparability in immunohistochemical studies. Un-
fortunately, generally accepted guidelines for optimal immunohis-
tochemistry protocol development are lacking [40,41]. Recently,
in a study investigating the clinical significance of p53 alterations
in prostate cancer, an immunohistochemistry protocol that was
deliberately designed to be ‘‘oversensitive’’ resulted in a much
higher rate of positive immunohistochemical findings (2.5%
positivity with the standard protocol compared with greater than
90% positivity with the ‘‘oversensitive’’ protocol) [42]. Facing this
problem, our group has established a comprehensive and highly
standardized protocol for an objective optimization of immuno-
histochemical stainings [40]. In conclusion, different protocols
produce different grades of sensitivity and specificity, which leads
to significant discrepancies in staining patterns and, as a result, in
the statistical data. Another source for statistical differences are
differences in sample sizes and divergent scoring systems. While
our protocol is optimized to measure both, the quantity and tha
intensity of the staining, Kahlert and colleagues have focused on
intensity only [29,40]. To preclude this as a reason for the
discrepant results, we have performed an analysis using staining
Figure 1. Representative immunohistochemical ALCAM stains of primary pancreatic cancer (PAC) lesions. (A) and (B) strong ALCAM
expression, (C) and (D) medium and (E) no expression. (F) Healthy pancreatic tissue. (G) Complete scan of the PAC tissue microarray.
doi:10.1371/journal.pone.0039018.g001
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(data not shown).
Nevertheless, not only did the majority of primary PAC lesions
express ALCAM, but metastatic and recurrent lesions also showed
a medium to strong expression (lymph node metastases 46%,
n=50; distant metastases 85%, n=7; recurrent tumor lesions
67%, n=15, data not shown). Similarly, Piscuoglio and colleagues
have described a significantly elevated expression in cancer of the
ampulla of Vater compared to healthy pancreatic samples and
adenoma [17]. These findings would suggest a potential involve-
ment of this factor in tumor progression of PAC [17].
This hypothesis stands in contrast to recent observations by
Zhang and colleagues, who identified non small-cell lung cancer
(NSCLC) stem cells, or tumor-initiating-cells by ALCAM specific
FACS sorting [13]. ALCAM positive NSCLC cells showed a high
proliferative potential in-vitro and in-vivo in contrast to ALCAM
negative cells. Interestingly, a knock-down of ALCAM resulted not
in a decrease of tumorigenicity, which is in accordance to the study
by Hong and colleagues who observed similar results in an
ALCAM silencing experiment of a PAC cell line via ALCAM
RNAi [37]. No effect on proliferation or migration was seen.
Furthermore, Zhang and colleagues presented immunohistochem-
ical results on the impact of ALCAM tissue expression on survival
Table 1. Association between the clinical and pathological parameters and the immunohistochemical ALCAM status of the
primary tumor and ALCAM serum (s-ALCAM) levels.
ALCAM IHC primary tumour Serum ALCAM level







(n=72, 37%) (n=84, 44%) (n=36, 19%) (n=62, 75%) (n=20, 25%)
Mean Age, years (range) 62.3 (33–83) 63.2 (33–87) 62.9 (43–82) 0.804 64.0 (31–92) 62.1 (48–76) 0.409
Sex
Male 108 39 (36%) 58 (54%) 11 (10%) 46 36 (78%) 10 (22%)
Female 84 33 (39%) 26 (31%) 25 (30%) 0.000 36 26 (72%) 10 (28%) 0.608
Tumour Staging (UICC 6
th edition)
Iau 6 2 (33%) 4 (67%) 0 (0%) 3 3 (100%) 0 (0%)
Ibu 26 8 (31%) 8 (31%) 10 (38%) 9 5 (56%) 4 (44%)
IIau 41 17 (41%) 18 (44%) 6 (15%) 14 11 (79%) 3 (21%)
IIbu 97 38 (39%) 44 (45%) 15 (16%) 43 31 (72%) 12 (28%)
IIIu 10 3 (30%) 5 (50%) 2 (20%) 6 6 (100%) 0 (0%)
IVu 12 4 (33%) 5 (42%) 3 (25%) 0.408 7 6 (86%) 1 (16%) 0.346
Tumour grading
1 and 2 106 38 (36%) 46 (44%) 22 (21%) 58 46 (79%) 12 (21%)
3 86 34 (40%) 38 (44%) 14 (16%) 0.710 24 16 (67%) 8 (33%) 0.264
doi:10.1371/journal.pone.0039018.t001
Figure 2. Kaplan-Meier overall survival analysis. (A) Immunohistochemical ALCAM staining of primary pancreatic cancer specimens and (B) low
and high s-ALCAM serum levels (patients who died during the first 30 days after surgery were excluded).
doi:10.1371/journal.pone.0039018.g002
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statistically significant effect. They concluded that ALCAM would
be a very robust, but inert cell-surface marker for NSCLC tumor-
initiating-cells. Since we have not found a significant clinical
association of ALCAM expression, ALCAM might well have a
similar role in PAC stem cells. If this hypothesis can be confirmed
by further in-vitro and in-vivo experiments, ALCAM might
become a potential target for novel antibody-based treatment
strategies. The usefulness of ALCAM as a drug target structure
may be further enhanced by the ligand-induced endocytosis of
ALCAM [23]. In addition, a recently described internalizing
single-chain antibody [23,24], targeting ALCAM has been
suggested for the potential intracellular delivery of various
therapeutic agents to prostate cancer cells. However, one
important objection must be raised: ALCAM is a ubiquitously
expressed molecule with physiologic roles in the intestinal mucosa
[43]. Severe effects on normal tissues might thus result and will
have to be taken into account when an application of systemic
specific cancer therapies is considered [43].
Because of the elevated expression of ALCAM in the majority of
the cancerous lesions, we also evaluated the levels of s-ALCAM
(from the ectodomain shedding of ALCAM) in blood sera. The s-
ALCAM values were significantly elevated in PAC patients
compared to patients with CP and the healthy blood donors
(p,0.001 and p,0.001, respectively; Figure 3A). The AUC
showed an acceptable discriminatory power of s-ALCAM
(AUC=0.690; Figure 3B). The sensitivity (58.6%) and specificity
(73.9%) of s-ALCAM was clearly inferior to the tumor marker
most frequently used for PAC, CA19-9, (sensitivity of 58% to 87%,
specificity of 93%) [44]. However, potential methodical weakness-
es of the study must be considered in the appraisal of the results:
Although the handling of the serum samples is standardized at our
institution, even small differences in the processing or handling can
have enormous effects [45]. Moreover, the study was retrospective
and conducted over a relatively long period. Hence, our results do
not exclude a potential usefulness of the s-ALCAM serum
quantification test, we believe the test should be further evaluated
in prospective trials with larger patient groups.
In order to determine the association of elevated s-ALCAM
levels with patient survival and tumor stage, different statistical
analyses were performed. Neither an analysis using s-ALCAM
levels as a continuous variable nor an categorical analysis with
different cut-off values showed significant associations with clinical
or histopathological parameters (Table 1 exemplarily shows the
results of the 75
th percentile as cut-off level). As already mentioned,
ALCAM might be an inert factor, which could explain the lack of
an association [13].
Recently, a potential role of ALCAM in gemcitabine-induced
chemoresistance in PAC was described, since ALCAM-silenced
PAC cells showed an induced chemoresistance [37]. Investigating
the clinical impact of the in-vitro data, we performed a sub-
analysis of patients receiving adjuvant chemotherapy regarding
survival (log-rank test). Patients with high or intermediate ALCAM
expression did not show a reduced or prolonged survival
compared to ALCAM negative patients (n=60, p=0.176).
Furthermore, no survival benefit was found in patients with
reduced s-ALCAM serum levels (75
th percentile, n=28,
p=0.672). Due to the retrospective character of the study, few
patients receiving adjuvant chemotherapy were identified, which
significantly limits the power of the analysis. Moreover, different
regimes were administered (Gemcitabine, Fluorouracil and
others). Further analysis should be performed with larger and less
heterogeneous patient cohorts, which might help to identify
patients who would benefit most from an adjuvant treatment and
also help tailor the best individual treatment for each patient.
The serum levels of s-ALCAM have been investigated in
pancreatic cancer before, but this study was the first to analyze
both ALCAM expression and s-ALCAM levels in the same
patients [36,37,38]. Surprisingly, no significant correlation or
association was found between the elevated tissue expression and
serum level in the patients (n=48, p=0.699). Recently, s-ALCAM
levels were investigated in breast and esophageal cancer patients
but no correlation with tissue expression was found [30,35]. This
might have several reasons: For example, the mere expression of
the ALCAM protein does not have to result in an increased
shedding of s-ALCAM by proteases such as ADAM17, which was
recently shown [29,30]. Furthermore, flushing of the shedded
Figure 3. S-ALCAM serum analysis. (A) s-ALCAM serum levels of the patients with pancreatic cancer (PAC) and chronic pancreatitis (CP) and
healthy control blood donors (p,0.001). (B) Receiver operating characteristic (ROC) curves of s-ALCAM for the diagnosis of PAC versus CP patients.
doi:10.1371/journal.pone.0039018.g003
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disruption of anatomical barriers surrounding host tissues and
endothelial cells. Taken together, the mechanisms regulating the
shedding of ALCAM and its dissemination into the surrounding
tissue and its entry into the blood system are barely understood
and further investigations are needed.
ALCAM is highly expressed in PAC specimens. The elevated
ALCAM expression in primary and metastatic sites of PAC might
perhaps make ALCAM a possible target for novel antibody-based
treatment strategies. The immunohistochemical results of our
study revealed no significant association between ALCAM
expression and clinical or pathological data in PAC patients. This
result is in clear contrast to further studies investigating the
expression of ALCAM in pancreatic cancer and several other solid
tumors of the gastrointestinal tract. Further efforts must be
undertaken to investigate the physiological and oncological role of
ALCAM and to validate the clinical usage of s-ALCAM as a
potential clinical marker for PAC.
Methods
Patients and Clinical Data
For this study, tissue specimens (n=264) and blood sera
(n=116) of patients with PAC and the sera of 115 patients with
CP treated at the Department of General, Visceral and Thoracic
Surgery, University Medical Center Hamburg-Eppendorf between
1993 and 2006 were analyzed. Blood samples were taken directly
before surgery. None of the patients received neoadjuvant
treatment. All data including sex, histology, tumor size, lymph
node metastasis, disease stage (UICC 6
th edition). Follow-up data
were obtained from a combination of clinical and pathological
record reviews, from outpatient clinic medical records and
communication with patients and their attending physicians, and
from the cancer registry. Overall survival was calculated from the
date of operation to the date of death or last follow-up. Patients
who did not survive the first 30 days after surgery were excluded
from the survival analysis.
The study was approved by the Ethics Committee of the
Chamber of Physicians in Hamburg, Germany. Written consent
for using the samples for research purposes was obtained from all
patients prior to surgery or blood drawing.
Tissue Microarray (TMA)
The pre-existing pancreatic cancer tissue microarray consists of
a total of 600 tissue samples [31,46]. These include 244 samples of
primary pancreatic adenocarcinoma, 116 lymph node metastases,
12 distant metastases and 23 local recurrences from 264 patients
with PAC. In addition, pancreatic tumors other than adenocar-
cinoma (endocrine, intraductal papillary mucinous neoplasms,
benign and malignant cystic tumors, and acinar cell tumors), a
standard control area containing 40 tumors from other organs,
healthy pancreatic tissues, and 18 healthy tissues from other sites
are included. Construction of the TMA was described previously
[47]. Briefly, haematoxylin-eosin stained sections were made from
selected primary tumor blocks (donor blocks) to define represen-
tative tumor regions. Tissue cylinders (0.6 mm in diameter) were
then punched from that region of the donor block using a home-
made semi-automated tissue arrayer. Sections of 3 mm in size were
cut using the Paraffin Sectioning Aid System (Instrumentics,
Hackensack, NJ, USA).
Immunohistochemical Staining for ALCAM and
Evaluation of ALCAM Expression
The ALCAM staining protocol was optimized in an extensive
and standardized multi-step procedure on various benign and
malignant tissues; the protocol was modified until selective staining
with the lowest background signals was established [40]. Freshly
cut TMA sections were analyzed on one day in a single
experiment. The expression of ALCAM was detected using a
mouse monoclonal antibody (clone MOG/07, 1:450; Novocastra,
Newcastle upon Tyne, UK) after the sections had been covered
with a citrate buffer, pH 7.8, and boiled in an autoclave. The
EnVision system (Dako, Glostrup, Denmark) was used to visualize
the immunostaining.
Only membranous staining was evaluated because cytoplas-
matic staining – if present – was always linked to stronger
membranous staining. The staining intensity (0, 1+,2 +,3 +) and
the fraction of positive tumor cells were scored for each tissue spot
as recently published [40]. Spots without staining and with a
staining intensity of 1+ in ,70% and 2+ in ,30% of the tumor
cells were scored as ALCAM low, medium scores were given for a
staining intensity of 1+ in $70%, 2+ in $30% or 3+ in ,30% of
the tumor cells, and high scores were given for a staining intensity
of 2+ in $70% or 3+ in $30% of the tumor cells. Immunohis-
tochemical analysis of the sections was performed without
knowledge of the patients’ identity or clinical status.
Sandwich ELISA for the Detection of s-ALCAM
For s-ALCAM quantification in peripheral blood, serum
samples of 116 Caucasian patients with PAC and 115 Caucasian
patients (37 female and 78 male, median age 50.1 years (31.4–79.2
years)) with CP, who were indicated for surgical treatment, were
analyzed with an s-ALCAM sandwich enzyme linked immunoas-
say (ELISA). All blood samples were obtained directly before
surgery. As healthy controls, 128 Caucasian blood-bank donors
(62 female and 66 male, median age 48.7 years 19.2–65.3 years)
were included in the study. All sera were processed latest after 4
hours [45].
For the detection of s-ALCAM, flexible 96-well microtiter plates
(Costar, Corning, NY, USA) were coated with 50 ml per well of
2 mg/ml of monoclonal mouse capturing antibody (MAB6561;
R&D Systems, Minneapolis, MN, USA) overnight at 4uC. The
wells were blocked with 3% w/v bovine serum albumin (BSA;
Fraktion V, 98% purity; Sigma Aldrich, Taufkirchen, Germany) in
PBS/T (PBS pH 7.3 containing 0.05% v/v Tween) for 45 min at
room temperature, and then incubated for 1 h at room
temperature with human serum samples diluted 1:50 in PBS.
After five washes with PBS/T, bound protein was detected by a
biotin-conjugated polyclonal antibody (BAF656; R&D Systems),
followed by streptavidin-conjugated peroxidase using 3,3’,5,5?-
tetramethylbenzidine (TMB) as the substrate. The color reaction
was stopped by the addition of 10 mM H2SO4, and analyzed at
450 nm using an ELISA reader (Dynatech MR 5000; Pegasus
Scientific, Rockville, MD, USA). Human Alcam–Fc protein (R&D
Systems) served as an internal standard for the assay.
In order to ensure that the immunoassay was suitable for
measuring clinical serum samples, reproducibility and linearity
were examined. The assay showed excellent linearity with serial
dilutions and showed ,10% coefficient of variation (CV) for the
intra- and inter-assay variability studies.
Statistical Analysis
The statistical analysis was performed using SPSS Statistics for
Windows (Version 17, SPSS Inc., Chicago Ill, USA). Interdepen-
ALCAM (CD166) in Pancreatic Cancer
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clinical data was calculated using Chi-square and Fisher’s exact
tests and displayed in cross tables. The cut-off level for s-ALCAM
quantification was determined using the Youden-index. Group
differences were calculated by the t-test, ANOVA; Mann-Whitney
or Kruskal-Wallis test. Receiver operating characteristic curves
were used to describe the performance of s-ALCAM. Survival
curves were plotted using the Kaplan-Meier method and analyzed
using the log-rank test. All tests were two-sided and p-values less
than 0.05 were considered statistically significant.
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